TKPHF (TKPHF) Stock Price & Analysis
TKPHF (TKPHF) rose 7.54% to USD 36.8 as of September 8, 2026 at 07:49 UTC, according to Nexqual real-time market data.
TKPHF last closed at USD 34.22; the session ranged USD 36.8–36.8 on volume of 100 shares. Market capitalization is $58.76B, with a 52-week range of USD 26.33–39.2 (PNK). Source: Nexqual, September 8, 2026 at 07:49 UTC.
Key Statistics (as of September 8, 2026 at 07:49 UTC)
| Price | USD 36.8 |
|---|---|
| Change | ▲ 7.54% (up) |
| Previous Close | USD 34.22 |
| Open | USD 36.8 |
| Day Range | USD 36.8 – 36.8 |
| 52-Week Range | USD 26.33 – 39.2 |
| Volume | 100 shares |
| Market Cap | $58.76B |
| Exchange | PNK |
Technical Analysis (TKPHF)
Nexqual's technical model rates TKPHF "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 07:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.76 (neutral) |
| vs SMA50 | Above (USD 34.24) |
| MACD | 0.31 (positive) |
Analyst Ratings (TKPHF)
Wall Street analysts rate TKPHF "None", per Nexqual as of September 8, 2026 at 07:49 UTC.
| Consensus Rating | None |
|---|
Earnings (TKPHF)
| Next Earnings Date | 2026-10-29 |
|---|---|
| Revenue Estimate | $1.16T |
Source: Nexqual, September 8, 2026 at 07:49 UTC.
Financials & Fundamentals (TKPHF)
| Total Revenue | $4.62T |
|---|---|
| Revenue Growth (YoY) | +10.20% |
| Gross Margin | +64.47% |
| Operating Margin | +16.45% |
| Profit Margin | -3.54% |
| ROE | -2.26% |
| Debt / Equity | 73.25 |
| Current Ratio | 1.14 |
| Total Cash | $460.98B |
| Total Debt | $5.54T |
| Free Cash Flow | $541.44B |
Source: Nexqual, September 8, 2026 at 07:49 UTC.
Financial Health Score (TKPHF)
Nexqual rates TKPHF's overall financial health "Solid" across five dimensions, as of September 8, 2026 at 07:49 UTC.
| Growth | Strong — Revenue +676% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 16% |
| Balance Sheet | Solid — $461.0B cash vs $5.54T debt |
| Cash Flow | Solid — FCF $541.4B, 12% margin |
| Efficiency | Critical — ROE -2%, ROA 2.7% |
Ownership (TKPHF)
| Insider Ownership | +0.03% |
|---|---|
| Institutional Ownership | +49.23% |
| Shares Outstanding | 1.60B |
| Float | 1.58B |
Source: Nexqual, September 8, 2026 at 07:49 UTC.
Leadership (TKPHF)
TKPHF is led by Julie Kim (age 55), CEO, President & Director, per Nexqual as of September 8, 2026 at 07:49 UTC.
| CEO, President & Director | Julie Kim (age 55) |
|---|---|
| CFO & Director | Milano Furuta (age 47) |
| President of Research & Development and Representative Director | Andrew S. Plump (age 60) |
| Chief Operating Officer | Michael Fox |
| Senior Vice President of Corporate Finance & Controlling Department | Iwaaki Taniguchi |
Major Backers & Investors (TKPHF)
Notable institutional backers of TKPHF include Capital Group, Fidelity, Goldman Sachs, according to Nexqual as of September 8, 2026 at 07:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 0.83% |
| Fidelity | 0.77% |
| Goldman Sachs | 0.64% |
| Capital Income Builder | 0.37% |
| Pacer Advisors, Inc. | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.41% |
| BlackRock | 1.5% |
Source: Nexqual, September 8, 2026 at 07:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 18.33 | ▼ 0.05% |
| ALPMF | Astellas Pharma, Inc. | USD 15.1 | ▲ 1.96% |
| CHGCY | Chugai Pharmaceutical Co., Ltd. | USD 21.59 | ▲ 0.09% |
| BAYZF | Bayer A.G. | USD 56.5 | ▼ 0.12% |
| MKKGY | Merck KGaA | USD 31.51 | ▼ 2.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:49 UTC. This page is informational and not investment advice.